REGN Nov 2024 1015.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:46PM EDT. Market open.
| Previous close | 59.76 |
| Open | 60.20 |
| Bid | 79.10 |
| Ask | 86.50 |
| Strike | 1,015.00 |
| Expiry date | 2024-11-15 |
| Day's range | 59.30 - 60.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
GlobeNewswireUpdated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
Simply Wall St.Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen stellar returns of 220% over the past five years
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
Investor's Business DailyWhy It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.
© 2024 Yahoo. All rights reserved.